.jpg "Kadmon Holdings (NYSE: KDMN)")
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kadmon Holdings (KDMN) today and set a price target of $25. The company’s shares closed on Friday at $2.64.
Fein noted:
“Our price target of $25 is based on a probability adjusted sum-of-parts $12 from KD025 in cGVHD + $12 from tesevatinib in PKD + $1 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller than anticipated commercial opportunity due to market sizing, competition, and pricing. Kadmon Holdings, Inc.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 11.2% and a 44.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on Kadmon Holdings is a Moderate Buy with an average price target of $13.95.
See today’s analyst top recommended stocks >>
Based on Kadmon Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $21.51 million. In comparison, last year the company had a GAAP net loss of $21.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine.
